downtown physical therapy, p.c.

285 grand street,
suite 201
new york, new york 10002

NYS Entity Status
ACTIVE

NYS Filing Date
SEPTEMBER 30, 2013

NYS DOS ID#
4465860

County
NEW YORK

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC PROFESSIONAL CORPORATION

Name History
2013 - DOWNTOWN PHYSICAL THERAPY, P.C.









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Restaurant Review: A New Kind of Sichuan Restaurant for New York
    By PETE WELLS - Tuesday Aug 1, 2017

    In downtown Flushing, Queens, Guan Fu Sichuan shows off the rich variety of flavors beyond the familiar blast of chiles.

    Source: NYT > Home Page
  • Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
    By Ben Fidler - Tuesday Sep 12, 2017

    Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]

    Source: Xconomy New York
  • Joël Robuchon Is Ready to Resurrect His New York Restaurant
    By FLORENCE FABRICANT - Tuesday Oct 24, 2017

    The French chef heads downtown to open his latest L’Atelier de Joël Robuchon and seek out a younger clientele.

    Source: NYT > Home Page
  • The Rebuilding Years, Post-Sandy
    By THE NEW YORK TIMES and JONAH MARKOWITZ - Sunday Oct 29, 2017

    Those affected by Hurricane Sandy five years ago shared how the storm changed their lives physically, emotionally and financially, and how things have changed for the better since.

    Source: NYT > Home Page
  • FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
    By Ben Fidler - Tuesday Aug 29, 2017

    The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]

    Source: Xconomy New York